A Phase 1 multicenter study evaluating the feasibility, safety, and efficacy of lonitoclax in patients with relapsed/refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and select low-grade lymphomas.
Latest Information Update: 17 Oct 2024
Price :
$35 *
At a glance
- Drugs Lonitoclax (Primary)
- Indications Chronic lymphocytic leukaemia; Lymphoma
- Focus Adverse reactions
- 17 Oct 2024 New trial record
- 16 Oct 2024 According to Expert Systems media release, Expert Systems proudly announces a major milestone in its partnership with Lomond Therapeutics, FDA clearance for Lomonds IND represents a key milestone in collaboration
- 15 Oct 2024 According to Lomond Therapeutics Media Release, announced that the U.S. Food and Drug Administration (FDA) has cleared Lomond's Investigational New Drug (IND) application for a Phase 1 multicenter study evaluating the feasibility, safety, and efficacy of lonitoclax in patients with relapsed/refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and select low-grade lymphomas.